JAK Inhibitors: What Is New?

Area of Science:

• Rheumatology
• Pharmacology
• Immunology

Background:

• Rheumatoid arthritis (RA) treatment has advanced with the introduction of targeted therapies.
• Janus kinase (JAK) inhibitors represent a significant development as oral small molecule targeted synthetic DMARDs (tsDMARDs).

Purpose of the Study:

• To review the recent clinical trial results of approved and pending JAK inhibitors for rheumatoid arthritis.
• To discuss the current understanding of JAK inhibitor efficacy and safety profiles in RA management.

Main Methods:

• Review of recently reported clinical trial data for JAK inhibitors in RA.
• Analysis of preclinical findings on JAK isoform selectivity.
• Evaluation of long-term safety studies and comparisons with biologic therapies.

Main Results:

• Multiple JAK inhibitors are approved or nearing approval for RA treatment.
• Preclinical studies suggest varying JAK isoform affinities, but clinical efficacy differences are not yet clear.
• Long-term safety data indicates signals similar to biologics, with specific concerns regarding VTE/PE risk for tofacitinib and baricitinib.

Conclusions:

• JAK inhibitors provide an oral small molecule alternative to biologics for RA, demonstrating comparable or improved efficacy.
• Further direct comparisons are needed to confirm potential differential safety profiles, such as with filgotinib.
• The advent of JAK inhibitors marks a major therapeutic advance in rheumatoid arthritis management.